Biophytis fait le point sur l'état d'avancement de SARA-INT, un essai clinique de phase 2b évaluant l'efficacité de Sarconeos (BIO101) dans le traitement de la sarcopénie

28 Aug 2020 19:00 CEST

Company Name

BIOPHYTIS

ISN

FR0012816825

Market

Euronext Growth

Symbol

ALBPS

See attachment(s) / Voir document(s) joint(s) / Zie bijlage / Ver documento(s) em anexo

16165_941945_Biophytis__SARAINT_update__CP_FR_vF.pdf

Source

BIOPHYTIS

Provider

Les Echos

Attachments

  • Original document
  • Permalink

Disclaimer

Biophytis SA published this content on 28 August 2020 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 August 2020 18:14:08 UTC